Clinical Trial Protocol
Iranian Registry of Clinical Trials

11 Jul 2026

Celecoxib as adjuant therapy in the treatment of OCD: a double blind randomized trial

Protocol summary

Summary

The objective of this randomized, double-blind, placebo controlled study is to test the hypothesis that the addition of Celecoxib would improve psychopathology in subjects with OCD treated with fluvoxamine. 50 patients with chronic DSM-IV-diagnosed OCD will receive fluvoxamine(100 mg/day) combined with either placebo (N=25) or 400mg/day celecoxib(N=25) for 10 weeks. Efficacy will be defined as the change from baseline to endpoint in score on the Yale-Brown obsessive compulsive scale(Y-B ocs).

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201312181556N56**
Registration date: **2013-12-23, 1392/10/02**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2013-12-23, 1392/10/02

Registrant information

Name
Shahin Akhondzadeh
Name of organization / entity
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5541 2222
Email address
s.akhond@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2014-01-05, 1392/10/15

Expected recruitment end date

2016-01-04, 1394/10/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Celecoxib as adjuant therapy in the treatment of OCD: a double blind randomized trial

Public title

Celecoxib in the treatment of obsessive-compulsive disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria: 1-Age between 18-60 years old, 2-Diagnosis of OCD based on DSM IV 3 , Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale-Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious cardiac, renal or hepatic disease ,5- receiving psychotropic medications during the last 6 weeks 6-pregnancy orbreast feeding 7-rising liver transaminases to three times the upper limit of normal or higher

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics Committee of Tehran University of Medical Sciences

Street address
Keshvarz Blvd

City
Tehran

Postal code

Approval date
2013-12-06, 1392/09/15

Ethics committee reference number
23218

Health conditions studied

1

Description of health condition studied
Obsessive- Cumpulsive Disorder

ICD-10 code
F42

ICD-10 code description
Obsessive-compulsive disorder

Primary outcomes

1

Description
Severity of symptoms of OCD

Timepoint
Baseline and weeks 2-4-6-8-10 after beginig of treatment

Method of measurement
Y_BOCS(Yale-Brown obsessive compulsive scale)

Secondary outcomes

empty

Intervention groups

1

Description
Tablet fluvoxamine (100 mg/day) combined with 400 mg/day of Tablets celecoxib as intervention group for 10 weeks

Category
Treatment - Drugs

2

Description
Tablet fluvoxamine (100 mg/day) combined with placebo as control group for 10 weeks

Category
Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center
Roozbeh Hospital

Full name of responsible person
Dr. Shahin Akhondzadeh

Street address
South Kargar Sreeet, Roozbeh Hospital

City
Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tehran University of Medical Sciences

Full name of responsible person
Dr masoud yunesian

Street address
Keshvarz Blvd

City
Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Tehran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
empty

Domestic or foreign origin
empty

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar Street; Roozbeh Hospital,
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Karegar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty